These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31177574)

  • 1. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
    Wang W; Tan J
    J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
    Chen XJ; He MJ; Zhou G
    J Oral Pathol Med; 2019 Oct; 48(9):832-839. PubMed ID: 31323146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
    Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
    Wang X; Zhao W; Zhang W; Wu S; Yan Z
    J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
    Sasabe E; Tomomura A; Yamamoto T
    J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
    Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
    PeerJ; 2023; 11():e15922. PubMed ID: 37663280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
    Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
    Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
    Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
    Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1-Mediated Regulation of Reactive Oxygen Species and Radioresistance in Oral Squamous Cell Carcinoma Cells.
    Takeshita H; Yoshida R; Inoue J; Ishikawa K; Shinohara K; Hirayama M; Oyama T; Kubo R; Yamana K; Nagao Y; Gohara S; Sakata J; Nakashima H; Matsuoka Y; Nakamoto M; Hirayama M; Kawahara K; Takahashi N; Hirosue A; Kuwahara Y; Fukumoto M; Toya R; Murakami R; Nakayama H
    Lab Invest; 2023 May; 103(5):100060. PubMed ID: 36801643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.
    Zhang LZ; Yang JG; Xia HF; Huang J; Liu HM; Wu M; Liu B; Wang WM; Chen G
    J Dent Res; 2023 Jul; 102(7):795-805. PubMed ID: 37246810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
    Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
    Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.